Recommended Topic Related To:

Aramine

"The U.S. Food and Drug Administration today expanded the approved use of Xgeva (denosumab) to treat adults and some adolescents with giant cell tumor of the bone (GCTB), a rare and usually non-cancerous tumor.

GCTB generally occurs in a"...

Aramine

Discontinued Warning IconPlease Note: This Brand Name drug is no longer available in the US.
(Generic versions may still be available.)

CLINICAL PHARMACOLOGY

The pressor effect of ARAMINE (metaraminol) begins in 1 to 2 minutes after intravenous infusion, in about 10 minutes after intramuscular injection, and in 5 to 20 minutes after subcutaneous injection. The effect lasts from about 20 minutes to one hour. ARAMINE (metaraminol) has a positive inotropic effect on the heart and a peripheral vasoconstrictor action.

Renal, coronary, and cerebral blood flow are a function of perfusion pressure and regional resistance. In patients with insufficient or failing vasoconstriction, there is additional advantage to the peripheral action of ARAMINE (metaraminol) , but in most patients with shock, vasoconstriction is adequate and any further increase is unnecessary. Blood flow to vital organs may decrease with ARAMINE (metaraminol) if regional resistance increases excessively.

The pressor effect of ARAMINE (metaraminol) is decreased but not reversed by alpha-adrenergic blocking agents. Primary or secondary fall in blood pressure and tachyphylactic response to repeated use are uncommon.

Last reviewed on RxList: 12/8/2004
This monograph has been modified to include the generic and brand name in many instances.

A A A

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Women's Health

Find out what women really need.


NIH talks about Ebola on WebMD